

RNS Number : 8239W
EKF Diagnostics Holdings PLC
06 February 2012

**EKF Diagnostics Holdings plc
("EKF" or the "Company" or the "Group")**

New US contract win

EKF Diagnostics Holdings plc (AIM: EKF), a worldwide manufacturer of point of care in-vitro diagnostic devices, announces that it has been awarded a contract to supply the State of New Mexico's Women, Infants, and Children (WIC) clinics with its point-of-care haemoglobin testing instrument, the HemoPoint[®] H2, and related cuvettes.

The initial order is for 220 instruments which will be supplied to over 100 WIC clinics throughout the US State and will be used to carry out tests for anemia. Anemia is one of the most common blood conditions in the US, affecting about 3.5 million Americans*.

An initial indication from the New Mexico WIC clinics suggests that they expect to perform more than 160,000 tests per year using the HemoPoint H2 instrument.

Julian Baines, Chief Executive of EKF, commented:

"Following on from our recent trading update, which showed strong trading for 2011 ahead of expectations, the news of this contract win reinforces our belief that EKF will deliver continued organic growth in 2012, particularly as we ramp up sales of our HemoPoint H2 instruments in the key market of North America."

**source: Centers for Disease Control and Prevention*

Enquiries:

EKF Diagnostics Holdings plc
David Evans, Executive Chairman
Julian Baines,
CEO

Tel: 029 2071 0570
Mob: 07740 084 452
Mob: 07788 420 859

Collins Stewart Europe Limited
Mark Dickenson / Jamie Adams

Tel: 020 7523 8000

Walbrook PR Limited
Paul McManus
Fiona Henson

Tel: 020 7933 8780
Mob: 07980 541 893 or paul.mcmanus@walbrookpr.com
Mob: 07886 335 992 or fiona.henson@walbrookpr.com

About EKF Diagnostics Holdings plc

EKF Diagnostics Holdings plc was formed in July 2010 following the acquisition of EKF-diagnostic GmbH for €14.32m and refocused its strategy to one of building a substantial point of care diagnostics business. As part of this strategy, the Group has integrated three further acquisitions, Quotient Diagnostics Limited (acquired in October 2010 for a maximum of £5.41m), Argutus Medical Limited (acquired in December 2010 for £2.18m) and Stanbio Laboratory L.P. (acquired in June 2011 for a maximum of US\$25.5m).

The Company, with its head office in Cardiff and operations in London, Germany, Poland, Russia, Ireland and the US, is a leading diagnostics business, focused on the development, production and distribution of chemical reagents and analysers for the testing of Glucose, Lactate, Haemoglobin, Haematocrit and HbA1c.

In May 2011 EKF entered into a distribution agreement with Alere Inc ("Alere"), a global diagnostics company, under which Alere was appointed the exclusive distributor of EKF's CLIA waived Hemo_Control device and cuvettes in the US, Canada and United Kingdom. The device is distributed in the US under the name HemoPoint H2.

For more information please visit the website: www.ekfdiagnostics.co.uk

This information is provided by RNS
The company news service from the London Stock Exchange

END

NRAEASASESSAEFF admin New US contract win 19858599 A Mon, 02/06/2012 - 07:00 Company
Announcement - General EKF